Is Axitinib a targeted drug?

Axitinib is a targeted drug. Axitinib is a second-generation tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors(VEGFR-1, VEGFR-2, VEGFR-3) play a role. Axitinib in combination with avelumab for the initial treatment of advanced renal cell carcinoma. In combination with pembrolizumab for the initial treatment of advanced renal cell carcinoma. It is also used as a monotherapy for advanced renal cell carcinoma(RCC) after failure of one systemic therapy.

54% (95% CI: 40–67) of patients in the alatinib titration group and 34% (95%) of the placebo group CI: 22–48) (unilateral P=0.19), compared with 59% (95% CI: 49–70) of nonrandomized patients.

Alatinib is a second-generation tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, ataxinib blocks angiogenesis, tumor growth, and metastasis. It is reported to exhibit 50-450 times greater potency than first-generation VEGFR inhibitors. Aaxitinib is an indazole derivative. 6It is commonly marketed under the trade name Inlyta and is available in oral dosage forms. Ataritinib prevents the development of cancer by inhibiting angiogenesis and preventing tumor growth. Alatinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2 and VEGFR-3. The plasma protein binding rate of aaxitinib is as high as 99% and most proteins are bound to albumin, followed by α1-Acid glycoprotein. There are generic drugs in Bangladesh. The retail price of Bangladesh Beacon Pharmaceutical is about 1,800 yuan for 5 mg and 60 tablets. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.

xa0

xa0